A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [31] Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
    Backlund, Ellen
    Yang, Muyi
    Grozman, Vitali
    Masucci, Giuseppe
    Falkenius, Johan
    Eriksson, Hanna
    Jovanovic, Braslav
    Hammarlund, Katarina
    Isacsson, Ulf
    Radu, Calin
    Abel, Edvard
    Karlsson, Kristin
    Palanco Zamora, Ricardo
    Wersall, Peter
    Edback, Ulrika
    Wickstrom, Stina
    Darai Ramqvist, Eva
    Egyhazi Brage, Suzanne
    Kiessling, Rolf
    Viktorsson, Kristina
    Franzen, Bo
    Lewensohn, Rolf
    Olofsson Bagge, Roger
    Ullenhag, Gustav J.
    Ny, Lars
    Lindberg, Karin
    Helgadottir, Hildur
    ACTA ONCOLOGICA, 2022, 61 (07) : 869 - 873
  • [32] Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma - A phase II study
    Astoul, P
    Picat-Joossen, D
    Viallat, JR
    Boutin, C
    CANCER, 1998, 83 (10) : 2099 - 2104
  • [33] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi
    Sureda, Anna
    Araujo, Luis
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Ilidia
    van der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
  • [34] The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
    Yi, L.
    Ning, Z.
    Xu, L.
    Shen, Y.
    Zhu, X.
    Yu, W.
    Xie, J.
    Meng, Z.
    ESMO OPEN, 2024, 9 (02)
  • [35] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1321 - 1328
  • [36] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    CANCERS, 2022, 14 (06)
  • [37] Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single Center Retrospective Study
    Higashiyama, T.
    Kuribayashi, K.
    Murakami, M.
    Kawamura, N.
    Kondo, T.
    Fujioka, T.
    Kandori, T.
    Tokuda, M.
    Negi, Y.
    Fujimoto, D.
    Otsuki, T.
    Mikami, K.
    Takahashi, R.
    Minami, T.
    Kijima, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S408 - S409
  • [38] Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
    Park, Sehhoon
    Lee, Yurimi
    Lee, Jiyun
    Min, Yang Won
    Kim, Hong Kwan
    Choi, Joon Young
    Jung, Hyun Ae
    Choi, Yong Soo
    Choi, Yoon-La
    Shim, Young Mog
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 567 - 579
  • [39] Anti-PD-1 antibody therapy for epithelial skin malignancies An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
    Ishii, Maki
    Hirai, Ikuko
    Tanese, Keiji
    Fusumae, Takayuki
    Nakamura, Yoshio
    Fukuda, Keitaro
    Uchi, Hiroshi
    Kabashima, Kenji
    Otsuka, Atsushi
    Yokota, Kenji
    Yamazaki, Naoya
    Namikawa, Kenjiro
    Fujimura, Taku
    Takenouchi, Tatsuya
    Yamamoto, Yuki
    Nishiguchi, Mana
    Sato, Yasunori
    Amagai, Masayuki
    Funakoshi, Takeru
    MEDICINE, 2020, 99 (44) : E22913
  • [40] Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
    Higashiyama, Tomoki
    Kuribayashi, Kozo
    Doi, Hiroshi
    Kubota, Aki
    Otsuki, Taiichiro
    Nakajima, Yasuhiro
    Mikami, Koji
    Takahashi, Ryo
    Nakamura, Akifumi
    Fujimoto, Daichi
    Kitajima, Kazuhiro
    Minami, Toshiyuki
    Kijima, Takashi
    ONCOLOGY, 2025,
12345